

BLISS GVS PHARMA LIMITED
 Regd Office, 102, Hyde Park, Sakivihar Road,
 Andheri (East), Mumbai - 400 072
AUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31.03.2011

SR. NO.	PARTICULARS	QUARTER ENDED		YEAR ENDED	
		31.03.2011 (AUDITED)	31.03.2010 (AUDITED)	31.03.2011 (AUDITED)	31.03.2010 (AUDITED)
1	SALES/INCOME FROM OPERATIONS (NET)	6016.48	4429.00	21883.81	16887.53
2	EXPENDITURE				
	a) INCREASED/DECREASE IN STOCK IN TRADE	175.74	(161.61)	(69.41)	(79.20)
	b) CONSUMPTION OF RAW MATERIALS	4284.71	2860.35	12027.84	6568.01
	c) PURCHASE OF TRADED GOODS	2.73	-	781.00	2568.44
	d) EMPLOYEE COST	104.19	80.62	430.47	328.12
	e) DEPRECIATION / AMORTISATION	106.7	109.61	546.95	540.11
	f) OTHER EXPENDITURE	896.02	843.08	2841.35	2406.97
	g) TOTAL	5570.09	3732.05	16558.20	12332.45
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & INTEREST (1-2)	446.39	696.95	5325.61	4555.09
4	OTHER INCOME	92.35	187.00	187.27	224.85
5	PROFIT BEFORE INTEREST (3+4)	538.74	883.95	5512.88	4779.94
6	INTEREST	68.44	66.41	214.73	204.41
7	PROFIT AFTER INTEREST BUT BEFORE TAX (5-6)	470.30	817.54	5298.14	4575.52
8	EXCEPTIONAL ITEMS	-	-	-	-
9	PROFIT BEFORE TAX (7-8)	470.30	817.54	5298.14	4575.52
10	TAX EXPENSE	7.82% 704.05	18.46% 77.60	24.21% 1235.11	27.09% 403.36
11	NET PROFIT AFTER TAX (9-10)	(233.75)	739.94	4063.03	4172.16
12	PAID - UP EQUITY CAPITAL	-3.89% 1031.47	16.71% 1031.47	18.57% 1031.47	24.71% 1031.47
13	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)			15630.62	12289.26
14	BASIC AND DILUTED EPS (NOT ANNUALISED)	0.23	0.72	3.94	4.04
15	AGGREGATE OF NON-PROMOTER SHAREHOLDING - NO. OF SHARES (FACE VALUE RS.1/- EACH) - PERCENTAGE OF SHAREHOLDING (%)	37300583 36.16	33634331 32.61	37300583 36.16	33634331 32.61
16	PROMOTER AND PROMOTER GROUP SHAREHOLDING				
	A) PLEDGE/ ENCUMBERED				
	- NO. OF SHARES (FACE VALUE RE.1/- EACH)	-	-	-	-
	- PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP)	-	-	-	-
	- PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY)	-	-	-	-
	B) NON - ENCUMBERED				
	- NO. OF SHARES (FACE VALUE RE.1/- EACH)	65846089	69512341	65846089	69512341
	- PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP)	100	100	100	100
	- PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY)	63.84	67.39	63.84	67.39

Statement of Assets and Liability as required under Clause 41 (V) (h) of Listing Agreement is as under:-

Particulars	(Rs. in lacs)	
	31.03.2011 (Audited)	31.03.2010 (Audited)
Funds Employed		
Share Capital	1031.47	1031.47
Reserves & Surplus	15630.62	12289.26
Loan Funds	823.94	764.21
TOTAL	17486.03	14084.94
Application of Funds		
Fixed Assets	2748.27	2361.51
Investments	170.01	0.01
Deferred Tax Asset (NET)	37.44	27.55
Current Assets, Loans and Advances		
a) Inventories	1161.13	3067.29
b) Sundry Debtors	11961.23	7040.98
c) Cash and Bank Balances	1798.30	1532.22
d) Other Current Assets	-	-
e) Loans and Advances	3473.10	1871.72
	18393.76	13512.21
Less: Current Liabilities and Provisions		
a) Liabilities	3444.13	1166.98
b) Provisions	419.32	649.35
	3863.45	1816.33
Net Current Assets	14530.31	11695.87
TOTAL	17486.03	14084.94

1. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.

2. DURING THE YEAR, COMPANY HAS PAID AN ADVANCE OF Rs.170.00 LACS TOWARDS THE JOINT VENTURE IN M/S.BLISS INDASI LIFE SCIENCES PVT. LTD. HOWEVER NO SHARES HAVE BEEN ISSUED TO THE COMPANY AS ON 31ST MARCH 2011.

3. PREVIOUS PERIOD FIGURES HAVE BEEN REGROUPED / REARRANGED WHEREVER NECESSARY.

4. THE BOARD HAS RECOMMENDED A DIVIDEND OF 30% I.E Rs.0.30 PER EQUITY SHARE FOR THE YEAR ENDED 31ST MARCH 2011.

5. DURING THE QUARTER, 9 COMPLAINTS WERE RECEIVED AND RESOLVED, THERE WERE NO COMPLAINTS PENDING AT THE BEGINING AND AT THE END OF THE QUARTER.

6. THE ABOVE RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE and WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON MAY 30TH, 2011.

FOR BLISS GVS PHARMA LIMITED

PLACE : MUMBAI
DATE : 30TH MAY 2011

SD/-
S.N.KAMATH
MANAGING DIRECTOR